leadf
logo-loader
RNS
viewAstraZeneca

AstraZeneca PLC - Directorate Change

RNS Number : 0735A
AstraZeneca PLC
25 September 2020
 

25 September 2020 07:00 BST

 

 

Non-Executive Board Appointment

 

 

AstraZeneca PLC today announced that with effect from 1 October 2020, Dr Euan Ashley is appointed as a Non-Executive Director and a member of the Science Committee.

 

Leif Johansson, Chairman of AstraZeneca, said: "We look forward to welcoming Euan to AstraZeneca and believe his scientific achievements and interests, which are well-aligned with our own BioPharmaceuticals R&D, together with his entrepreneurial experience on the US west coast will enable him to make a significant contribution to the Board's work."

 

Euan Ashley is Associate Dean and Professor of Cardiovascular Medicine and Genetics at Stanford University in CaliforniaDr Ashley's research focuses on genetic mechanisms of cardiovascular health and disease.  In addition to wet bench science, his laboratory leverages artificial intelligence and digital health tools, working with biotechnology and technology partners in Silicon Valley, to advance both translational and clinical research.

 

Dr Ashley studied physiology and medicine at Glasgow University, completing his junior doctor training at Oxford University Hospitals NHS Trust, before undertaking a DPhil in cardiovascular cellular biology and molecular genetics at the University of Oxford.  In 2002, he moved to Stanford University to train in cardiology and advanced heart failure.

 

Dr Ashley has received many awards including recognition from the Obama White House for contributions to personalized medicine and the American Heart Association's Medal of Honor for precision medicine.

 

No disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASELESLESSEIU

Quick facts: AstraZeneca

Price: 7880

Market: LSE
Market Cap: £103.41 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read